HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review

HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review

The approval of CDK4/6 inhibitors has dramatically improved care for the treatment of HR+/HER2– advanced breast cancer, but navigating the rapidly-expanding treatment evidence base is challenging. In this narrative review, we provide best-practice recommendations for the first-line treatment of HR+/...

Full description

Bibliographic Details
Main Authors: Katarzyna J. Jerzak, Nathaniel Bouganim, Christine Brezden-Masley, Scott Edwards, Karen Gelmon, Jan-Willem Henning, John F. Hilton, Sandeep Sehdev
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Current Oncology
Subjects:
advanced breast cancer
CDK4/6 inhibitors
HR+/HER2–
mutational testing
treatment considerations
Online Access:https://www.mdpi.com/1718-7729/30/6/411

Internet

https://www.mdpi.com/1718-7729/30/6/411

Similar Items